From StructContinue beyond “Raw-material costs are back in management’s vocabulary”Back to the brief ↗Feed / NTRA

Natera, Inc.

NTRA

Healthcare · 309.83 -0.3% today

You’ve read what changed. Here’s whether the market is confirming it.

Partial group confirmationMarket checked 14 Aug, 15:55 GMT-4

Jodie situation report

Natera, Inc.'s move is being confirmed by its market group.

NTRA accounts for 5.3% of the group's measured movement across 4.8 effective names. raw member direction is mixed; 4 of 7 SPY-adjusted paths align to the upside. Capital-flow agreement is 1%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

SPY-adjusted 5m paths
Role in the moveAligned contributor#6 of 7 by movement share
Group movement share5.3%Absolute path energy—not portfolio weight
Relative path+0.50%aligned
Effective breadth4.8 / 7broad
Relative alignment4/7upside path · 3 counter-moving
Capital-flow agreement1%not yet clean
SEQUENCE READ

MRNA, VCYT moved materially before NTRA. NTRA crossed its material path threshold at 09:45 ET. CAI, GH, CRSP followed.

EVIDENCE COVERAGE

5 of 7 members in Cancer Diagnostics are active. 0 of 8 disclosed connections are confirming.

What would change this read
  • At least 5 of 7 durable members become active together.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as PSNL begins moving with the group.

Invalidation: The live read weakens if participation falls to 2 of 7 members or fewer.

Watch this read

Who this business touches

The relationships behind NTRA

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

ILMNIllumina, Inc.supplierFeb 27, 2026 ▾

“For example, our molecular diagnostics tests are currently only validated to perform on Illumina’s sequencing platform; in addition, Illumina is currently the sole supplier of our sequencers and related reagents for Panorama, Horizon, Signatera and Prospera,…”

ILMNIllumina, Inc.partnerFeb 27, 2026 ▾

“If we seek to achieve marketing authorization for Panorama, to the extent that Panorama incorporates Illumina’s sequencer or sequencing reagents, we may require Illumina’s cooperation in the regulatory process.”

Depended on by

PSNLPersonalis, Inc.customerMay 7, 2026 ▾

“First Quarter 2026 Highlights Total revenue of $15.5 million decreased 25%, or $5.1 million, during the first quarter of 2026 compared to the first quarter of 2025, due to (i) lower revenue from pharma testing services and other customers; (ii) an expected re…”

Filing peers

MYGNBLLNGH

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 29 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

NTRA is currently a Follower in the organic co-movement group Cancer Diagnostics. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.